These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20414658)

  • 1. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
    Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
    Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
    J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
    Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
    Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
    Ueda K; Yokoyama M; Asai H; Koudaira M; Yamada S; Katsube A; Mishima Y; Sakajiri S; Takeuchi K; Saotome T; Terui Y; Takahashi S; Hatake K
    Gan To Kagaku Ryoho; 2010 May; 37(5):853-7. PubMed ID: 20495315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
    Yoon DH; Choi DR; Ahn HJ; Kim S; Lee DH; Kim SW; Park BH; Yoon SO; Huh J; Lee SW; Suh C
    Eur J Haematol; 2010 Aug; 85(2):149-57. PubMed ID: 20477862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
    Rueda A; Sabin P; Rifá J; Llanos M; Gómez-Codina J; Lobo F; García R; Herrero J; Provencio M; Jara C;
    Hematol Oncol; 2008 Mar; 26(1):27-32. PubMed ID: 17868190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.